VEGFR2/CD309 Protein (glycosylated, Monomer, Soluble)

N° du produit ABIN1589571

Cette protéine Recombinant VEGFR2/CD309 est exprimée dans Cellules d'insectes.

Aperçu rapide pour VEGFR2/CD309 Protein (glycosylated, Monomer, Soluble) (ABIN1589571)

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Type de proteíne: Recombinant

Activité biologique: Active

Origine: Souris

Source: Cellules d'insectes

Pureté: > 95 % by SDS-PAGE

Détail du produit

Attributs du protein: glycosylated, Monomer, Soluble

Fonction: VEGFR-2/Flk-1 (native), soluble

Séquence: ASVGLTGDFL HPPKLSTQKD ILTILANTTL QITCRGQRDL DWLWPNAQRD SEERVLVTEC GGGDSIFCKT LTIPRVVGND TGAYKCSYRD VDIASTVYVY VRDYRSPFIA SVSDQHGIVY ITENKNKTVV IPCRGSISNL NVSLCARYPE KRFVPDGNRI SWDSEIGFTL PSYMISYAGM VFCEAKINDE TYQSIMYIVV VVGYRIYDVI LSPPHEIELS AGEKLVLNCT ARTELNVGLD FTWHSPPSKS HHKKIVNRDV KPFPGTVAKM FLSTLTIESV TKSDQGEYTC VASSGRMIKR NRTFVRVHTK PFIAFGSGMK SLVEATVGSQ VRIPVKYLSY PAPDIKWYRN GRPIESNYTM IVGDELTIME VTERDAGNYT VILTNPISME KQSHMVSLVV NVPPQIGEKA LISPMDSYQY GTMQTLTCTV YANPPLHHIQ WYWQLEEACS YRPGQTSPYA CKEWRHVEDF QGGNKIEVTK NQYALIEGKN KTVSTLVIQA ANVSALYKCE AINKAGRGER VISFHVIRGP EITVQPAAQP TEQESVSLLC TADRNTFENL TWYKLGSQAT SVHMGESLTP VCKNLDALWK LNGTMFSNST NDILIVAFQN ASLQDQGDYV CSAQDKKTKK RHCLVKQLII LGMEASLGDR IAMP

Attributs du produit: Length (aa):654

Information d'application

Indications d'application: Measured by its ability to inhibit the VEGF165-induced proliferation in human umbilical vein endothelial (HUVE) cells.

Commentaires:

Soluble Receptors

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: The lyophilized mouse sFlk-1 is soluble in water and most aqueous buffers, it should be reconstituted in water or PBS to a concentration of not lower than 100 μg/mL.

Buffer: 25 mM MES, 100 mM NaCl, pH 5.5

Stock: 4 °C,-20 °C,-80 °C

Stockage commentaire: The material is stable for greater than six months at -20° C to -70° C. After the first thawing it is recommended to aliquote the material, because repeated freeze-thaw cycles will decrease the activity. Store at 4°C not longer than 2 days.

Date de péremption: 6 months

Détail du antigène

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Autre désignation: VEGFR-2/Flk-1

Sujet: Disruption of the precise balance of positive and negative molecular regulators of blood and lymphatic vessel growth can lead to myriad diseases. Although dozens of natural inhibitors of hemangiogenesis have been identified, an endogenous selective inhibitor of lymphatic vessel growth has not to our knowledge been previously described. A splice variant of the gene encoding vascular endothelial growth factor receptor-2 (VEGFR-2) that encodes a secreted form of the protein, designated endogenous soluble VEGFR-2 (esVEGFR-2/KDR) has been described. The endogenous soluble esKDR inhibits developmental and reparative lymphangiogenesis by blocking VEGF-C function. Tissue-specific loss of esKDR in mice induced, at birth, spontaneous lymphatic invasion of the normally alymphatic cornea and hyperplasia of skin lymphatics without affecting blood vasculature. Administration of esKDR inhibited lymphangiogenesis but not hemangiogenesis induced by corneal suture injury or transplantation, enhanced corneal allograft survival and suppressed lymphangioma cellular proliferation. Naturally occurring esKDR thus acts as a molecular uncoupler of blood and lymphatic vessels, modulation of esKDR might have therapeutic effects in treating lymphatic vascular malformations, transplantation rejection and, potentially, tumor lymphangiogenesis and lymphedema. Recombinant human esKDR generated by alternative splicing consist of the first 6 Ig-like loops followed by the unique C-terminal end: GMEASLGDRIAMP.
Synonyms: soluble vascular endothelial growth factor receptor-2, Kdr, Flk1, Ly73, Flk-1, VEGF receptor 2, VEGFR-2, sVEGFR-2

Poids moléculaire: 105 kDa

ID gène: 16542

UniProt: P35918

Pathways: Signalisation RTK, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling